|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|
| Revenue | |||
| Product | |||
| Grant And Other Revenue | |||
| Total revenue | |||
| Operating costs and expenses: | |||
| Cost of product revenue | |||
| Sales and marketing | |||
| Research and development | |||
| General and administrative | |||
| Impairment of long-lived assets | |||
| Restructuring expense | |||
| Total operating costs and expenses | |||
| (Loss) income from operations | |||
| Interest income | |||
| Interest expense | |||
| Change in fair value of redeemable convertible preferred stock warrants | |||
| Change in fair value of convertible notes | |||
| Loss on extinguishment of debt | |||
| Tax credits | |||
| Other income (expense), net | |||
| Net (loss) income before income taxes | |||
| Income tax expense (benefit) | |||
| Net (loss) income | |||
| Net (loss) income per share attributable to common stockholders – basic (in dollars per share) | |||
| Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – basic (in shares) | |||
| Net (loss) income per share attributable to common stockholders – diluted (in dollars per share) | |||
| Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – diluted (in shares) |
Loading...
